Total medical devices industry cross border deals worth $3bn were announced globally for April 2022, with the $1.2bn private equity deal with Natus Medical being the sector’s biggest investment, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked an increase of 114.3% over the previous month of $1.4bn and a drop of 57.1% when compared with the last 12-month average of $7bn.

In terms of number of cross border deals, the sector saw a drop of 32.79% with 41 deals in April 2022 when compared to the last 12-month average of 61 deals.

In value terms, North America led the activity with cross border deals worth $1.9bn in April 2022.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

medical devices industry cross border deals in April 2022: Top deals

The top five cross border deals accounted for 77.9% of the overall value during April 2022.

The combined value of the top five cross border deals stood at $2.33bn, against the overall value of $3bn recorded for the month.

The top five medical devices industry cross border deals of April 2022 tracked by GlobalData were:

1) ArchiMed $1.2bn private equity deal with Natus Medical

2) The $541.63m acquisition of Phenox by Wallaby Medical

3) CVS Health,Export Development Bank of Iran,General Atlantic,Mass Mutual Ventures,Openspace Ventures,Sequoia Capital and SoftBank Vision Fund II $300m venture financing deal with Biofourmis

4) The $150m venture financing of BostonGene by Impact Investment Partners,Japan Industrial Partners and NEC

5) Integer $141.73m acquisition deal with Aran Biomedical